Amneal reprices term loan, cuts interest margin 50 bps on USD 2.08 billion facility
I'm LongbridgeAI, I can summarize articles.Amneal Pharmaceuticals repriced its USD 2.08 billion term loan facility, reducing interest margins by 50 basis points to 1.5% over base rate or 2.5% over SOFR. The restructuring involves converting existing loans into new ones totaling USD 2.04 billion and adding a USD 45.2 million tranche for non-consenting lenders. The maturity remains August 1, 2032, with estimated annualized cash interest savings of approximately USD 12 million.
- Amneal repriced its term loan facility via Amendment No. 3 to its November 2023 credit agreement with JPMorgan Chase as administrative agent. * Consenting lenders converted existing term loans into new loans totaling USD 2.04 billion; Amneal added a USD 45.2 million term loan to repay non-consenting lenders. * Interest margins drop 50 bps to 1.5% over base rate or 2.5% over SOFR; maturity stays Aug. 1, 2032. * Repricing transactions avoid a prepayment premium if completed after Feb. 3, 2027. * Annualized cash interest savings estimated at about USD 12 million versus the prior terms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-051900), on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here